NPC1 as a Modulator of Disease Severity and Viral Entry of SARSCoV- 2

(E-pub Ahead of Print)

Author(s): Cecilia Vial, Juan Francisco Calderón, Andrés D. Klein*

Journal Name: Current Molecular Medicine

Become EABM
Become Reviewer


The COVID-19 plague is hitting mankind. Several viruses, including SARS-CoV-1, MERS-CoV, EBOV, and SARS-CoV-2, use the endocytic machinery to enter the cell. Genomic variants in NPC1, which encodes for the endolysosomal Niemann-Pick type C1 protein, restricts the host-range of viruses in bats and susceptibility to infections in humans. Lack of NPC1 and its pharmacological suppression inhibits many viral infections including SARS-CoV-1 and Type I Feline Coronavirus Infection. Antiviral effects of NPC1-inhibiting drugs for COVID-19 treatment should be explored.

Keywords: COVID-19, SARS-Cov-2, Niemann-Pick C1, modifier gene, drug repurposing, virus, infection.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1566524020666200713175426
Price: $95

Article Metrics

PDF: 15